9,138 Shares in ICU Medical, Inc. $ICUI Acquired by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust bought a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 9,138 shares of the medical instruments supplier’s stock, valued at approximately $1,096,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ICUI. Inscription Capital LLC boosted its stake in ICU Medical by 407.9% in the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock valued at $1,003,000 after acquiring an additional 6,718 shares in the last quarter. Simon Quick Advisors LLC acquired a new position in shares of ICU Medical during the second quarter worth $275,000. AlphaQuest LLC lifted its holdings in shares of ICU Medical by 3,058.3% during the 2nd quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock valued at $200,000 after purchasing an additional 1,468 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new stake in shares of ICU Medical during the 3rd quarter valued at $521,000. Finally, Magnetar Financial LLC acquired a new stake in shares of ICU Medical in the 2nd quarter worth $378,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Trading Down 3.7%

ICU Medical stock opened at $152.67 on Friday. The stock has a 50-day moving average price of $146.95 and a 200 day moving average price of $132.89. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -492.47 and a beta of 0.80. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $175.51.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The firm had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. During the same quarter in the prior year, the business earned $1.59 earnings per share. The business’s quarterly revenue was down 8.9% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Sell-side analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

Insider Activity at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the sale, the director owned 3,995 shares of the company’s stock, valued at $560,977.90. This trade represents a 24.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the sale, the vice president owned 5,456 shares in the company, valued at approximately $776,607.04. This represents a 14.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Monday, January 19th. KeyCorp boosted their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday. Finally, Piper Sandler increased their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average target price of $175.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.